Showing papers on "Protein Z published in 2015"
TL;DR: Plasma ZPI levels increased significantly in the OVX group after surgery when compared with the pre-operation levels, clearly indicating that estrogen did not contribute to the plasma ZPI concentrations.
5 citations
02 Dec 2015
TL;DR: The chapter presents the current genetics and molecular biology knowledge of the most important DNA polymorphisms in thrombosis-related genes encoding coagulation factor V (FV), coagulating factor II (FII), coAGulation factor XII (FXII) and protein Z (PROZ).
Abstract: Genetic association studies have revealed a correlation between DNA variations in genes encoding factors of the hemostatic system and thrombosis-related disease. Certain var‐ iant alleles of these genes that affect either gene expression or function of encoded protein are known to be genetic risk factors for thrombophilia. The chapter presents the current genetics and molecular biology knowledge of the most important DNA polymorphisms in thrombosis-related genes encoding coagulation factor V (FV), coagulation factor II (FII), coagulation factor XII (FXII), coagulation factor XIII A1 subunit (FXIIIA1), 5,10methylene tetrahydrofolate reductase (MTHFR), serpine1 (SERPINE1), angiotensin I-con‐ verting enzyme (ACE), angiotensinogen (AGT), integrin A2 (ITGA2), plasma carboxypeptidase B2 (CPB2), platelet glycoprotein Ib α polypeptide (GP1BA), thrombo‐ modulin (THBD) and protein Z (PROZ). The molecular detection methods of each DNA polymorphism is presented, in addition to the current knowledge regarding its influence on thrombophilia and related thrombotic events, including stroke, myocardial infarction, deep vein thrombosis, spontaneous abortion, etc. In addition, best thrombosis prevention strategies with a combination of genetic counseling and molecular testing are discussed.
3 citations
TL;DR: It is concluded that PZ G79A polymorphism is not a risk factor for puerperal CVT in Indian women and there was no significant difference in the clinical features of patients with and without the polymorphism.
Abstract: Protein Z (PZ), a cofactor for PZ-dependent protease inhibitor, is known to play an important role in inhibiting the coagulation cascade. The aim of the study was to investigate whether PZ G79A polymorphism is a risk factor for puerperal cerebral venous thrombosis (CVT). A total of 71 patients with puerperal CVT and 98 healthy controls were genotyped for PZ 79GA polymorphism by polymerase chain reaction-restriction fragment length polymorphism method. In patients, the genotype distribution for GG, GA, and AA genotypes was 22.5%, 43.7%, and 33.8%, and in controls, 25.5%, 40.8%, and 33.7%, respectively. The risk associated with carrying the mutant genotype (GA and AA) versus the wild GG genotype was found to be 1.11 (95% confidence interval: 0.52-2.35; P = .909). There was no significant difference in the clinical features of the patients with and without the polymorphism. We therefore conclude that PZ G79A polymorphism is not a risk factor for puerperal CVT in Indian women.
3 citations
TL;DR: An independent association between increasing blood levels of protein Z in SLE rather than in DM patients and an increased risk for ischemic stroke is demonstrated.
Abstract: Introduction A number of clinical studies that explored the role of protein Z in coronary heart disease, ischemic stroke, and deep vein thrombosis patients have been published. Particularly in ischemic stroke, patients or at least subgroups of patients with low levels (in the convalescent phase of stroke) or high levels (in the acute phase of stroke) of protein Z have been associated with increased risk of stroke.
Aim of the work This cross-sectional study aimed to investigate the role of protein Z in patients with systemic lupus erythematosus (SLE) and/or diabetes mellitus (DM) to determine the association between protein Z serum concentration and acute ischemic stroke in these patients.
Patients and methods The study was carried out on selected 40 stroke patients divided into 20 patients with SLE and 20 without SLE, who were further divided equally into diabetic and nondiabetic patients. Assessment included demographic data (age, height, weight, and BMI), clinical examination, laboratory investigations including complete blood count, erythrocyte sedimentation rate, HbA1c, lipid profile, protein Z level, MRI-brain, and extracranial carotid duplex ultrasound.
Results As regards protein Z levels, it was 4.4 ± 0.6 μg/ml in group I (DM+SLE), 3.0 ± 0.8 μg/ml in group II (SLE + no DM), 2.6 ± 0.8 μg/dl in group III (no SLE, no DM), and 1.1 ± 0.6 μg/dl in group IV (no SLE + DM), which demonstrated a significant difference between the four groups, with the highest protein Z serum level in group I.
Conclusion Our study demonstrated an independent association between increasing blood levels of protein Z in SLE rather than in DM patients and an increased risk for ischemic stroke. However, it remains unclear whether elevated protein Z concentrations are a cause or a consequence of ischemic stroke.
1 citations
TL;DR: Protein Z dependent protease inhibitor and ZPI, の総説執筆を中断して本稿を書き始めたが,何しろ 本テーマの終日の前日に本誌編集長に問い合 わせたところ,
Abstract: プロテイン Z(PZ)依存性プロテアーゼインヒビ ター(ZPI)は,前世紀末に登場してから 10数年以上 の年月が経過したが,未だに謎に満ちたタンパク 質である.GW最終日の前日に本誌編集長に問い合 わせたところ「大々至急」との回答が届いたので,他 の総説執筆を中断して本稿を書き始めたが,何しろ 本テーマについては研究費が取れないため原著論文 も連続的には出せないし,総説を書くのも 2005年以 来で 10年振りである .因みに,GW最終日に「医 学中央雑誌」で「プロテイン Z」を検索したところ,僅 か 34件しかヒットせず,その内 3件は別物であった. 「プロテイン Z依存性プロテアーゼインヒビター」に 至っては1件のみで,われわれの本学会の抄録であっ た.これほどまでに国内で人気のないテーマである のは,偏にヒトにおける「病的意義」が不明であるか らであろう.ついでに PubMedを「Protein Z」で検索 すると 385件がヒットしたが,無論,植物タンパク 質やウイルスタンパク質が混在している.「Protein Z dependent protease inhibitor」では 83件に減る.以上 のような悲惨な状況であるので,本稿では主に ZPI の生理的であると「思われる」機能構造関連について 述べる.なお,後述するように ZPIの機能の半分に は PZが関与しているので,関連する PZについて 責任者連絡先: 山形大学医学部分子病態学講座 〒 990-9585 Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan Tel: 023-628-5276,Fax: 023-628-5280 E-mail: aichinos@med.id.yamagata-u.ac.jp 一瀬白帝